



**CONDENSED INTERIM THREE  
MONTHS FINANCIAL  
STATEMENTS SEPT 30, 2023**

**CITI PHARMA**

Email: [info@citipharma.com.pk](mailto:info@citipharma.com.pk)

Tel: 042 - 35316587

Website: [www.citipharma.com.pk](http://www.citipharma.com.pk)

Address: 588-Q, Johar Town Lahore



# TABLE OF CONTENTS

## Company Information

Company Profile .....	3
Director's Report .....	4
Financial Statements .....	6

# COMPANY INFORMATION

## Board of Directors

Mr. Nadeem Amjad  
Chairman

Mr. Rizwan Ahmad  
Chief Executive Officer

Dr. Zameer Ul Hassan  
Executive Director

Ms. Saira Aslam  
Non-Executive Director

Mr. Muhammad Naeem  
Non-Executive Director

Mr. Abdul Jaleel Shaikh  
Independent Director

Ms. Farzin Khan  
Independent Director

## AUDIT COMMITTEE

Mr. Abdul Jaleel Shaikh (Independent Director)  
Mr. Nadeem Amjad (Non-Executive Director)  
Mr. Muhammad Naeem (Non-Executive Director)

## Human Resource & Remuneration Committee

Ms. Farzin Khan (Independent Director)  
Mr. Zameer Ul Hassan Shah (Executive Director)  
Mr. Rizwan Ahmad (Executive Director)

## Chief Financial Officer

Mr. Asif Iqbal

## Company Secretary & Head of Legal

Mr. Muhammad Riaz

## Head of Internal Auditor

Muhammad Ishaq

## External Auditors

Aslam Malik & Co.  
Chartered Accountants

## Legal Advisors

Muhammad Riaz

## Share Registrar

F.D Registrar Services (Pvt) Ltd

## Bankers

Habib Metropolitan Bank Limited  
Habib Bank Limited- Islamic  
Pak Brunei Investment Company Limited

Samba Bank Limited  
Soneri Bank Limited  
Bank of Punjab Limited  
National Bank of Pakistan  
Bank Al Habib Limited  
Meezan Bank Limited  
Standard Chartered Bank (Pakistan) Limited

## Head Office

588-Q Block, M.A., Johar Town, Lahore  
Tel: +92-42-35316587

## Registered Office

3-KM, Head Balloki Road, Bhai Pheru, Distt Kasur

Tel: +92-49-4510189, 4513392

Fax: +92-49-4510191

E-Mail: [corporate@citipharma.com.pk](mailto:corporate@citipharma.com.pk)

Website: [www.citipharma.com.pk](http://www.citipharma.com.pk)



## DIRECTORS REPORT

The Directors of Citi Pharma Limited (the “Company”) are pleased to present the un-audited financial information for three months period ended September 30, 2023. This financial information is submitted in accordance with Section 227 of the Companies Act, 2017.

### FINANCIAL HIGHLIGHTS

The company's net sales of Rs. 2.7 billion have decreased by 13.37%, and the gross margin of Rs. 123.9 million has seen a reduction of 33.46% compared to the corresponding period last year. This decline can be attributed to the overall economic crisis in the country, which includes rising production costs, rupee devaluation, import difficulties, escalating inflation, and soaring fuel prices. Nevertheless, we maintain a strong sense of optimism that the stabilization of the Forex PKR exchange rate and the decrease in input costs will lead to an improvement in the situation in the months to come.

### FUTURE OUTLOOK

The pharmaceutical industry is still grappling with rising costs resulting from the devaluation of the Pak Rupee. Given this situation, making necessary price adjustments to account for inflation is of paramount importance for sustaining the business. Nevertheless, there is always hope on the horizon, and we remain highly optimistic and confident about the prospects of economic recovery in the Country.

The Company remains steadfast in its commitment to optimizing business allocation for the Company's best interests. Furthermore, we will persist in investing in our human capital and nurturing a compassionate culture that fosters collaboration, creativity, and innovation.



**(Rizwan Ahmad)**  
**Chief Executive Officer**

Lahore

Dated: October 27, 2023

## ڈائریکٹرز رپورٹ

سٹی فارورڈ لمیٹڈ (کمپنی) کے ڈائریکٹرز 30 ستمبر 2023 کو ختم ہونے والی سرمایہ کے لیے غیر آڈٹ شدہ مالیاتی گوشواروں کو پیش کرتے ہوئے خوشی محسوس کر رہے ہیں۔ یہ مالیاتی گوشوارہ کنٹینر ایکٹ 2017 کے سیکشن 227 کے مطابق جمع کرائے گئے ہیں۔


## مالیاتی چمکیں

کمپنی کی خالص فروخت 2.7 بلین روپے رہی جو کہ 13.37 فیصد کم ہوئی، اور مجموعی مارجن 123.9 بلین روپے رہا جس میں گزشتہ سال کی اسی مدت کے مقابلے میں 33.46 فیصد کمی دیکھی گئی ہے۔ اس کمی کو ملک کے مجموعی معاشی بحران کی وجہ قرار دیا جاسکتا ہے، جس میں پیداواری لاگت میں اضافہ، روپے کی قدر میں کمی، درآمدی مشکلات، مہنگائی میں اضافہ اور ایندھن کی بڑھتی ہوئی قیمتیں شامل ہیں۔ اس کے باوجود، ہم اس امید کے مشروط احساس کو برقرار رکھتے ہیں کہ فاریکس پالیسی پاکستانی روپیہ کی شرح تبادلہ میں استحکام اور پیداواری لاگت میں کمی آئندہ مہینوں میں صورتحال میں بہتری کا باعث بنے گی۔

## مشعل کا منظر

فارورڈ سٹیونٹیل کی صنعت کا اب بھی پاکستانی روپے کی قدر میں کمی کے نتیجے میں زیادہ لاگت کا سامنا ہے۔ اس صورت حال کے پیش نظر، کاروبار کو برقرار رکھنے کے لیے مہنگائی کے حساب سے قیمتوں میں ضروری ایڈجسٹمنٹ کرنا انتہائی اہم ہے۔ اس کے باوجود، افق پر ہمیشہ امید رہتی ہے، اور ہم ملک میں اقتصادی بحالی کے امکانات کے بارے میں انتہائی پُر امید اور پُر اعتماد ہیں۔

کمپنی، کمپنی کے بہترین مفادات میں کاروباری شخصیتوں کو بہتر بنانے کے اپنے عزم میں ثابت قدم ہے۔ مزید برآں، ہم اپنے انسانی سرمائے میں سرمایہ کاری کرنے اور ایک ہمدردانہ ثقافت کو پروان چڑھانے پر قائم رہیں گے جو تعاون، تخلیقی صلاحیتوں اور جدت کو فروغ دیتا ہے۔



(رضوان احمد)

چیف ایگزیکٹو آفیسر

لاہور

تاریخ: 12 ستمبر 2023ء

**CITI PHARMA LIMITED**  
**CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION**  
**AS AT SEPTEMBER 30, 2023**

	September 30, 2023 (Un-audited)	June 30, 2023 (Audited)
Note	-----Rupees-----	
<b>EQUITY AND LIABILITIES</b>		
<b>SHARE CAPITAL AND RESERVES</b>		
<b>Authorised Capital:</b>		
300,000,000 Ordinary shares of Rs. 10/- each	<b>3,000,000,000</b>	<b>3,000,000,000</b>
<b>Issued, subscribed and Paid up Capital:</b>		
228,461,200 ( June 2022: 228,461,200) Ordinary shares of Rs. 10/- each	2,284,612,000	2,284,612,000
Share Premium	1,391,532,000	1,391,532,000
Revenue reserves-Unappropriated profits	1,482,086,324	1,387,634,785
Surplus on revaluation of freehold land	309,294,525	309,294,525
	<b>5,467,524,849</b>	<b>5,373,073,310</b>
<b>LIABILITIES</b>		
<b>NON CURRENT LIABILITIES</b>		
Long Term Financing - Secured	6,977,361	8,541,062
Deferred Liabilities	155,958,629	144,584,190
Deferred Grant	469,579	582,493
Lease Liabilities	3,186,024	4,366,411
	<b>166,591,592</b>	<b>158,074,156</b>
<b>CURRENT LIABILITIES</b>		
Trade and other payables	2,053,102,322	2,165,170,443
Due to Related Parties	134,915,434	297,480,434
Short Term Borrowings-Secured	1,574,398,700	1,470,571,476
Current Portion of Long Term Liabilities-Secured	51,592,966	64,585,799
Unclaimed Dividend	461,696	461,696
Accrued Mark Up	71,038,067	61,558,378
Provision for taxation	459,414,454	393,188,922
	<b>4,344,923,639</b>	<b>4,453,017,148</b>
Contingencies and Commitments	-	-
	<b>9,979,040,080</b>	<b>9,984,164,614</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		
<b>ASSETS</b>		
<b>NON CURRENT ASSETS</b>		
Property, plant and equipment	3,033,630,968	3,051,888,220
Work in Progress	91,069,094	70,386,258
Long term security deposits	23,645,564	23,645,564
Long Term Advance to Associated Company	254,540,900	254,540,900
	<b>3,402,886,526</b>	<b>3,400,460,942</b>
<b>CURRENT ASSETS</b>		
Stock in Trade	2,633,293,898	2,608,983,575
Trade Debts- Unsecured	1,762,960,609	1,882,148,741
Short Term Investments (TDRs)	1,444,024,839	1,514,904,826
Advances deposits, prepayments and other receivables	692,208,432	523,058,370
Cash and bank balance	43,665,776	54,608,160
	<b>6,576,153,554</b>	<b>6,583,703,672</b>
	<b>9,979,040,080</b>	<b>9,984,164,614</b>

The annexed notes form an integral part of these condensed interim financial statements.



Chief Executive



Chief Financial Officer



Director

CITI PHARMA LIMITED  
 CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)  
 FOR THE PERIOD ENDED SEPTEMBER 30, 2023

	Quarter Ended	
	September 30, 2023 (Un-audited)	September 30, 2022 (Un-audited)
Notes		
<b>Sales- Net</b>	2,701,228,267	3,118,074,356
Cost of sales	(2,454,760,271)	(2,747,684,203)
<b>Gross profit</b>	<b>246,467,996</b>	<b>370,390,153</b>
Administrative expenses	48,262,551	49,715,005
Selling and Distribution expenses	38,634,053	37,663,377
	<b>(86,896,605)</b>	<b>(87,378,383)</b>
<b>Operating Profit</b>	<b>159,571,391</b>	<b>283,011,771</b>
Financial Charges	(86,808,489)	(157,053,888)
	<b>72,762,902</b>	<b>125,957,882</b>
Other income/(Loss)	106,208,183	47,598,134
	<b>178,971,084</b>	<b>173,556,016</b>
Other Expenses	(12,344,735)	(4,219,670)
<b>Profit before Taxation</b>	<b>166,626,349</b>	<b>169,336,346</b>
Taxation	(72,174,810)	(23,527,710)
<b>Profit for the period</b>	<b>94,451,539</b>	<b>145,808,636</b>
<b>Earnings per share (EPS)</b>		
- Basic and Diluted	<b>0.41</b>	<b>0.64</b>

The annexed notes form an integral part of these condensed interim financial statements.



Chief Executive



Chief Financial Officer



Director

CITI PHARMA LIMITED  
 CONDENSED INTERIM STATEMENT OF COMPREHENSIVE INCOME (UN-AUDITED)  
 FOR THE PERIOD ENDED SEPTEMBER 30, 2023

	Note	Quarter Ended	
		September 30, 2023 (Un-audited)	September 30, 2022 (Un-audited)
Profit for the period		94,451,539	145,808,636
Other comprehensive income for the period		-	-
Item that will not be reclassified subsequently to Profit or Loss			
Revaluation Surplus on freehold Land		-	-
<b>Total comprehensive income for the Period</b>		<b>94,451,539</b>	<b>145,808,636</b>

The annexed notes form an integral part of these condensed interim financial statements.



Chief Executive



Chief Financial Officer



Director

**CITI PHARMA LIMITED**  
**CONDENSED INTERIM STATEMENT OF CASH FLOWS (UN-AUDITED)**  
**FOR THE PERIOD ENDED SEPTEMBER 30, 2023**

**September 30, 2023** **September 30, 2022**  
**(Un-audited)** **(Un-audited)**

-----Rupees-----

**CASH FLOW FROM OPEARTING ACTIVITIES**

**Profit Before Taxation for the period**

**Adjustments For Non- Cash Items And Other Line Items:**

	166,626,349	169,336,346
Depreciation	31,186,520	21,617,496
Financial Charges	86,808,489	157,053,888
Unrealized Income	19,617,724	17,546,713
Amortisation of Deferred Grant	(648,992)	(20,695,433)
Gratuity Expense	5,425,162	958,272
Worker's Profit Participation Fund	8,948,554	2,161,912
Worker's Welfare Fund	3,396,181	2,057,758
	154,733,638	180,700,606

**Profit/ (Loss) before working capital changes**

**321,359,987** **350,036,952**

**Effect of working capital changes**

Advances, Deposits And Prepayments	(12,278,781)	4,002,787
Trade Debts	119,188,132	(248,664,732)
Stock In Trade	(24,310,323)	118,113,943
Trade And Other Payables	(124,412,857)	735,292,171
	<b>(41,813,829)</b>	<b>608,744,169</b>

Financial Charges Paid

(76,962,983) (153,773,881)

Income Tax Paid

(156,871,282) (118,255,539)

Worker's Profit Participation Fund

- (28,581,969)

(233,834,265) (300,611,389)

**Net cash flow from operating activities**

**A 45,711,893 658,169,732**

**CASH FLOW FROM INVESTING ACTIVITIES**

Purchase Of Property, Plant & Equipment	(12,929,268)	(3,573,121)
Paid for Capital Work in Progress	(20,682,836)	(280,634,335)
Short Term Investments	43,115,349	15,012,246

**Net cash flow from investing activities**

**B 9,503,246 (269,195,210)**

**CASH FLOW FROM FINANCING ACTIVITIES**

Proceeds less repayment of Long Term Financing	(14,239,352)	(327,726,794)
Lease Rentals Paid	(1,327,310)	(1,410,535)
Due to related parties	(162,565,000)	
Short Term Borrowings	103,827,224	(225,078,435)

**Net Cash flow From Investing Activities**

**C (74,304,438) (554,215,764)**

**Net Increase/ (decrease) in cash and cash equivalents**

**A+B+C (19,089,299) (165,241,242)**

Cash and cash equivalents at beginning of the period

1,411,532,062 1,658,116,564

**Cash and cash equivalents at end of the period**

**1,392,442,763 1,492,875,322**


**Cash and cash equivalents comprise of:**

Cash in hand	325,341	283,763
Cash at bank	43,340,435	166,956,250
Short Term Investments	1,348,776,987	1,325,635,309
	<b>1,392,442,763</b>	<b>1,492,875,322</b>

The annexed notes form an integral part of these condensed interim financial statements.



Chief Executive



Chief Executive Officer



Director


CITI PHARMA LIMITED  
 CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY (UN-AUDITED)  
 FOR THE PERIOD ENDED SEPTEMBER 30, 2023

PARTICULARS	SHARE CAPITAL	SHARE PREMIUM	REVENUE RESERVES	SURPLUS ON REVALUATION	TOTAL
----- Rupees -----					
<b>Balance as at June 30, 2022- (Audited)</b>	<b>2,284,612,000</b>	<b>1,391,532,000</b>	<b>728,539,802</b>	<b>309,294,525</b>	<b>4,713,978,327</b>
<b>Total Comprehensive Income for the Quarter</b>					
Profit for the period	-	-	145,808,636	-	145,808,636
Other comprehensive income	-	-	-	-	-
	-	-	145,808,636	-	145,808,636
<b>Balance as at September 30, 2022- (Un-audited)</b>	<b>2,284,612,000</b>	<b>1,391,532,000</b>	<b>874,348,438</b>	<b>309,294,525</b>	<b>4,859,786,963</b>
<b>Balance as at June 30, 2023- (Audited)</b>	<b>2,284,612,000</b>	<b>1,391,532,000</b>	<b>1,387,634,785</b>	<b>309,294,525</b>	<b>5,373,073,310</b>
<b>Total Comprehensive Income for the Quarter</b>					
Profit for the period	-	-	94,451,539	-	94,451,539
Other comprehensive income	-	-	-	-	-
	-	-	94,451,539	-	94,451,539
<b>Balance as at September 30, 2023- (Un-audited)</b>	<b>2,284,612,000</b>	<b>1,391,532,000</b>	<b>1,482,086,324</b>	<b>309,294,525</b>	<b>5,467,524,849</b>

The annexed notes form an integral part of these condensed interim financial statements.



Chief Executive



Chief Executive Officer



Director

## 1 STATUS AND NATURE OF BUSINESS

The company was incorporated as a private limited company in Pakistan under the Repealed Companies Ordinance, 1984 on October 08, 2012. The principal activity of the company is manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. The company was converted into public unlisted company with effect from October 13, 2020 and Company was listed on Pakistan Stock Exchange on July 09, 2021. The registered office of the company is situated at 3 KM, Head Balloki Road, Phool Nagar, Kasur. The Head office of the company situated at 588 Q Block, Johar Town, Lahore.

## 2 BASIS OF PREPARATION

### 2.1 Statement of Compliance

This condensed interim financial information are unaudited and have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting. The accounting and reporting standards as applicable in Pakistan for interim financial reporting comprise of:

- International Accounting Standard 34, 'Interim Financial Reporting, issued by International Accounting Standards Board (IASB) as notified under the Companies Act, 2017; and
- Provisions of and directives issued under the Companies Act, 2017.

Where the provisions of and directives issued under the Companies Act, 2017 differ with the requirements of IAS 34, the provisions of and directives issued under the Companies Act, 2017 have been followed.

The Comparative condensed interim statement of financial position presented has been extracted from annual audited financial statements for the year ended June 30, 2023, whereas the comparative condensed interim profit or loss, condensed interim statement of other comprehensive income, condensed interim statement of cash flows and condensed interim statement of changes in equity have been extracted from unaudited condensed interim financial statements for the three months ended September 30, 2022.

### 2.2 Basis of Measurement

These financial statements have been prepared under the historical cost convention using accrual basis of accounting, except for condensed interim statement of cash flows.

### 2.3 Functional and presentation currency

These financial statements are presented in Pakistan Rupees which is Company's functional currency.

### 2.4 Accounting Estimates and Judgement Used

The preparation of this condensed interim financial information in conformity with the approved accounting and reporting standards requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Company's accounting policies. Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectation of future events that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.

During preparation of this condensed interim financial information, the significant judgments made by the management in applying the Company's accounting policies and the key sources of estimation and uncertainty are the same as those that apply to the financial statements for the year ended June 30, 2023.

## 3 SIGNIFICANT ACCOUNTING POLICIES

The accounting policies and methods of computation adopted in the preparation of these condensed interim financial statements are consistent with those applied in the preparation of the unconsolidated annual audited financial statements for the year ended June 30, 2023.

### 3.1 Change in accounting standards, interpretations and amendments to published accounting and reporting standards

#### 3.1.1 Amendments to published accounting and reporting standards which became effective during the period:

There were certain amendments to accounting and reporting standards which became mandatory for the Company during the period. However, the amendments did not have any significant impact on the financial reporting of the Company and, therefore, have not been disclosed in these unconsolidated condensed interim financial statements.

#### 3.1.2 Amendments to published accounting and reporting standards that are not yet effective:

There are certain amendments to the accounting and reporting standards that will be mandatory for the Company's annual accounting periods beginning on or after July 1, 2023. However, these amendments will not have any significant impact on the financial reporting of the Company and, therefore, have not been disclosed in these condensed interim financial statements.

**4 SHARES CAPITAL**

**Authorized share capital**

300,000,000 Ordinary shares of Rs. 10/- each

**Issued, subscribed and paid up capital**

**Opening Balance**

117,692,000 Ordinary shares of Rs. 10 each, fully paid in cash

110,769,200 Ordinary Share of Rs. 10 each issued as fully paid Bonus shares

**Movement During the period / year**

**Closing Balance**

117,692,000 Ordinary shares of Rs. 10 each, fully paid in cash

110,769,200 Ordinary Share of Rs. 10 each issued as fully paid Bonus shares

228,461,200 Ordinary shares of Rs. 10/- each

**5 LONG TERM FINANCING - SECURED**

Long term loan from Pak Brunei Investment Company

Term finance against purchase of machinery from Bank Al-Habib Limited

Finance of Machinery in SBP (TERF) from Bank Al-Habib Limited

Current Portion shown under current liabilities

	September 30, 2023 (Un-audited)	June 30, 2023 (Audited)
	3,000,000,000	3,000,000,000
	1,176,920,000	1,176,920,000
	1,107,692,000	1,107,692,000
	-	-
	1,176,920,000	1,176,920,000
	1,107,692,000	1,107,692,000
	<b>2,284,612,000</b>	<b>2,284,612,000</b>
	15,625,000	21,875,000
	6,525,000	9,570,716
	28,027,758	32,971,394
	<b>50,177,758</b>	<b>64,417,110</b>
	(43,200,397)	(55,876,047)
	<b>6,977,361</b>	<b>8,541,062</b>

5.1 This loan is obtained from Pak Brunei Investment company which carries mark up of three months KIBOR + 250 bps and is repayable in 48 installments. The loan was secured against fixed assets and now it is collateralized against Joint Pari Passu Charge.

5.2 Term Finance Facility is obtained from the Bank Al Habib Limited with mark up of three months KIBOR + 225 bps and is repayable in 48 installments, which is secured against the specific assets.

5.3 The Company has also obtained long term loans of Rs. 84.64 million for financing import of plant and machinery from Bank Al-Habib Limited, which is secured against the specific assets. The rate of markup on these loans are at 5% per annum which include 4% BAH share and 1% SBP share. These loans are for four years and are repayable in fifteen equal quarterly instalments under SBP TERF scheme including three month grace period from the date of disbursement and mark up to be recoverable on quarterly basis.

**6 DEFERRED GRANT**

As at 01 July

Received during the year

Derecognition of Grant

Amortization

Current portion

As at period/year end

	3,625,811	46,671,792
	-	-
	-	(38,067,524)
	(648,992)	(4,978,457)
	2,976,819	3,625,811
	(2,507,240)	(3,043,317)
	<b>469,579</b>	<b>582,493</b>

**7 LEASE LIABILITIES**

The amount of future minimum lease payments along with their present value and the period during which they fall due are as under:

Not later than one year

Later than one year but not later than five years

Less: Finance charge

Less: Current maturity of long term obligation

Payable within one year

Payable after one year

	4,057,764	6,750,609
	6,047,719	4,651,301
	10,105,483	11,401,910
	(1,034,130)	(1,369,064)
	<b>9,071,353</b>	<b>10,032,846</b>
	(5,885,329)	(5,666,435)
	<b>3,186,024</b>	<b>4,366,411</b>
	5,885,329	5,666,435
	3,186,024	4,366,411
	<b>9,071,353</b>	<b>10,032,846</b>

7.1 The Company entered into lease agreements with financial institutions to acquire vehicles. The liabilities under the lease agreements are payable in equal monthly installments and are subject to finance charges at the rates ranging from 6 months KIBOR + 2.5% per annum (June 30, 2023 : 6 months KIBOR + 2.5% to 3.95% per annum). The lease liabilities are secured against security deposits, post dated cheques and also secured against financed vehicles.

## 8 CONTINGENCIES AND COMMITMENTS

### 8.1 Contingencies

There were no known contingencies as at period end.

### 8.2 Commitments

Commitments of the Company under Ijarah Lease is as follow:

September 30, 2023  
Rupees

June 30, 2023  
Rupees

The amount of future Payments under Ijarah lease and the period under which these become due are as follows:

Not later than one year	12,685,735	13,274,858
Later than one year but not later than five years	26,975,754	29,965,205
	<b>39,661,489</b>	<b>43,240,063</b>

## 9 PROPERTY PLANT & EQUIPMENT

Operating fixed assets

9.1

3,021,878,021

3,039,139,260

Right of Used Assets

9.2

11,752,947

12,748,960

**3,033,630,968**

**3,051,888,220**

### 9.1 Operating Fixed Assets

Opening Written down value as at July 01

3,039,139,260

2,228,126,382

Addition during the period/year

12,929,268

898,412,851

Disposal during the period/year

-

-

Revaluation Surplus on Land

-

-

**12,929,268**

**898,412,851**

Depreciation charged for the period/ year

(30,190,507)

(87,399,973)

Closing written down value

**3,021,878,021**

**3,039,139,260**

#### 9.1.1 Details of additions during the period/year as follows:

Freehold Land

-

443,498,900

Building on Freehold Land

1,553,716

175,701,678

Plant & Machinery

5,703,542

270,597,054

Office Equipments

4,037,930

6,421,903

Furniture and Fixtures

1,634,080

1,673,943

Computers

-

519,372

**12,929,268**

**898,412,850**

### 9.2 Right of Used Assets

Opening Balance

12,748,960

15,936,200

Addition during the period/year

-

-

Depreciation charged during the period/year

(996,013)

(3,187,240)

Closing Balance

**11,752,947**

**12,748,960**

## 10 TRANSACTION WITH RELATED PARTIES

The Related parties comprise principal shareholders and their affiliates, directors, companies with common directorship and key management personnel. Details of transactions and balances at period end with related parties, other than those which have been disclosed elsewhere in these condensed interim financial statements, are as follows:

		Quarter Ended	
		September 30, 2023	September 30, 2022
		-----Rupees-----	
<b>10.1 Transaction for the period</b>			
	<b>Nature</b>	<b>Relationship</b>	
	Salary	CEO	3,300,000
	Salary	Directors	1,700,000
	Director's Loan Paid	Directors	(56,100,000)
	Loan return to Associated Company namely Citi Technologies (Pvt) Ltd	Associated Company	(106,465,000)
	Directors Meeting Fee	Directors	185,000
	Finance Income from Yaqeen Developers Limited	Associated Company	14,756,398
			3,300,000
			4,050,000
			-
			-
			185,000
			-

## 11 UTILIZATION OF PROCEEDS FROM INITIAL PUBLIC OFFERING

The principal purpose of the issue was to increase the capacity in both segment of Active Pharmaceutical Ingredients (API) and Formulation and to set up a state of the art, 200 bed hospital facility in Lahore.

Estimated break-up of utilization of the IPO proceeds is mentioned below:

Description	Funds Required (Rupees)	Allocation (%)	Actual Expenditure (Rupees)	Excess/ (Less) Incurred (Rupees)
<b>API Segment</b>				
Civil Works	150,000,000	7%	153,750,654	3,750,654
Procurement of Plant and Machinery	405,194,500	20%	216,187,580	(189,006,920)
	<b>555,194,500</b>	<b>27%</b>	<b>369,938,234</b>	<b>(185,256,266)</b>
<b>Formulation Segment</b>				
Civil Works	250,000,000	12%	140,470,130	(109,529,870)
Procurement of Plant and Machinery	307,630,000	15%	234,730,605	(72,899,395)
	<b>557,630,000</b>	<b>27%</b>	<b>375,200,735</b>	<b>(182,429,265)</b>
<b>Hospital Facility</b>				
Civil Work of Hospital Building (incl. Electrical and Mechanical work)	668,000,000	33%	-	(668,000,000)
Plant and Machinery for Hospital	254,551,500	13%	-	(254,551,500)
	<b>922,551,500</b>	<b>46%</b>	<b>-</b>	<b>(922,551,500)</b>
<b>Utilization of Excess Proceeds</b>				
Repayment of Borrowings	54,197,497	19%	54,197,497	-
Working Capital Requirement	108,902,639	37%	108,902,639	-
IPO Expenses	127,667,864	44%	127,667,864	-
	<b>290,768,000</b>	<b>100%</b>	<b>290,768,000</b>	<b>-</b>

## 12 FINANCIAL RISK MANAGEMENT AND FAIR VALUE DISCLOSURES

### 12.1 Financial risk management information and disclosures

These condensed interim financial statements do not include all financial risk management information and disclosures which are required in the annual financial statements and should be read in conjunction with the Company's annual financial statements for the year ended June 30, 2023. There have been no change in any risk management policies since the year end.

### 12.2 Fair Value of Financial Instrument

IFRS - 13 Fair Value Measurement establishes a single source of guidance under the IFRS for the fair value measurements and disclosures about the fair value measurement where such measurements are required as permitted by other IFRSs. It defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an ordinary transaction between market participants at the measurement date (i.e. an exit price).

## 13 EVENTS AFTER THE REPORTING PERIOD

There are no other significant events after the reporting period which may require adjustment of and/or disclosure in these financial statements.

## 14 DATE OF AUTHORIZATION FOR ISSUE

These condensed interim financial statements were authorized for issue on **October 27, 2023** by the board of directors of the company.

## 15 GENERAL

The figures have been rounded off to the nearest rupees.

Corresponding figures have been rearranged, and reclassified, where necessary, for better presentation and disclosure.



Chief Executive



Chief Financial Officer



Director